SCHEMBL16633410

SCHEMBL16633410

COc1cc2[nH]c3c(c2cc1OC)C1(CC1)CN(C(C)=O)[C@@H]3c1ccc(Cl)cc1OC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 7/20 0.41
HTR2C P28335 7/20 0.41
HTR2B P41595 5/20 0.41
HTR1A P08908 2/20 0.41
HTR1D P28221 2/20 0.41
HTR1B P28222 2/20 0.41
HTR1E P28566 2/20 0.41
HTR7 P34969 2/20 0.41
HTR3A P46098 2/20 0.41
HTR5A P47898 2/20 0.41
HTR6 P50406 2/20 0.41
SIGMAR1 Q99720 2/20 0.41
ADRB1 P08588 1/20 0.41
KIF11 P52732 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
HIF1A Q16665 1/20 0.37
SIRT1 Q96EB6 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2032538 1.00 HTR2A (0.41) HTR2AHTR2CHTR2BHTR1AHTR1D
SCHEMBL2029034 0.93 HTR2A (0.46) HTR2AHTR2CHTR2BHTR1AHTR1D
SCHEMBL2033538 0.90 HTR2A (0.45) HTR2AHTR2CHTR2BHTR1AHTR1D
SCHEMBL2032088 0.90 KIF11 (0.47) HTR2AHTR2CKIF11KDM4EALDH1A1
SCHEMBL2034575 0.90 KIF11 (0.38) HTR2AHTR2CKIF11SMN1; SMN2KDM4E
SCHEMBL2029300 0.89 HTR2C (0.42) HTR2AHTR2CHTR2BHTR1AHTR1D
SCHEMBL2030005 0.87 KIF11 (0.42) HTR2AHTR2CHTR2BHTR1AHTR1D
Ono-2952 SCHEMBL2033676 0.85 MAPT (0.39) HTR2AHTR2CHTR2BHTR1AHTR1D
Ono-2952 SCHEMBL2032485 0.85 MAPT (0.39) HTR2AHTR2CHTR2BHTR1AHTR1D
Ono-2952 SCHEMBL31518699 0.85 MAPT (0.39) HTR2AHTR2CHTR2BHTR1AHTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150105415-A1 TRICYCLIC COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105415-A1 TRICYCLIC COMPOUND AND USE THEREOF SI, ALPI, SLC10A2 HTR2A 1711/4885HTR2C 893/4885HTR2B 1835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.